Wayne Rackoff

Medicine · Health Sciences

20h-index3.9kcitations46works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(9), Hemoglobinopathies and Related Disorders(8), Neutropenia and Cancer Infections(7), Acute Myeloid Leukemia Research(5), Erythropoietin and Anemia Treatment(5)

Publications46 total

Supplementary Data from Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia
2023Open Access
Supplementary Figures S1-S3 from Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia
2023Open Access
Data from Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia
2023Open Access
Supplementary Figures S1-S3 from Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia
2023Open Access
Supplementary Data from Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia
2023Open Access
Data from Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia
2023Open Access
Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
Journal of Clinical Oncology·2019· 10 cited
SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Journal of Clinical Oncology·2018· 13 cited
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
New England Journal of Medicine·2018· 1.3k citedOpen Access
SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
Queensland's institutional digital repository (The University of Queensland)·2018
A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds
Clinical Pharmacology & Therapeutics·2015· 42 cited
Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.
Blood·2009
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
Journal of Clinical Oncology·2009· 116 citedOpen Access
Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.
Cancer Research·2009· 5 cited
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
Journal of Clinical Oncology·2007· 644 citedOpen Access
Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia
Clinical Cancer Research·2007· 76 cited
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
Blood·2007· 81 citedOpen Access
Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients
The Oncologist·2007· 40 citedOpen Access
A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma
The Oncologist·2007· 82 citedOpen Access
Double-Blind, Placebo-Controlled Study of Quality of Life, Hematologic End Points, and Safety of Weekly Epoetin Alfa in Children With Cancer Receiving Myelosuppressive Chemotherapy
Journal of Clinical Oncology·2006· 99 cited
page 1 of 3Next →

Frequent Co-authors

Jean‐Luc Harousseau(9), Jeffrey E. Lancet(9), Bob Löwenberg(9), Richard M. Stone(9), Mitch Raponi(8), Yi Zhang(6), Yixin Wang(6), David C. Atkins(6), Jeffrey D. Hord(5), Marilyn Hockenberry(5), Pamela S. Hinds(5), Fred Saad(4), Boris Hadaschik(4), Julie N. Graff(4), David Olmos(4), Paul N. Mainwaring(4), Hiroji Uemura(4), Angela Lopez‐Gitlitz(4), Byron M. Espina(4), Eric J. Small(4)